Tissue Repair Ltd is a clinical-stage biopharmaceutical company focused on the development of advanced wound healing therapies. Its primary mission is to address unmet needs in the treatment of chronic wounds, such as venous leg ulcers, as well as to provide aftercare solutions for patients following cosmetic and medical procedures. Central to its product portfolio are innovative agents like TR-987, a topical drug currently in Phase III clinical trials intended for chronic wound management, and TR Pro+, a gel designed for post-procedural skin care and regeneration. Tissue Repair utilizes proprietary technologies, including Glucoprime, which activates targeted immune pathways to enhance tissue repair and skin regeneration. The company’s research and development activities are rooted in immunogenic science, leveraging genetically driven pattern recognition to accelerate natural healing responses. Operating within the biotechnology sector, Tissue Repair Ltd has positioned itself as a leader in wound care innovation in Australia, with a broader vision of improving outcomes in healthcare settings where advanced regenerative solutions are crucial. Since its founding in 2012, the company’s unwavering focus has been on translating clinical research into practical therapies that have the potential to make a significant impact across the healthcare and aesthetic industries.